Xspray Announces 2 Poster Presentations for XS004 in Chronic Myeloid Leukemia (CML) at the American Society of Hematology (ASH) 2022 Annual Meeting
Press release 2022-11-03
Xspray Pharma AB (NASDAQ Stockholm: XSPRAY), a biopharmaceutical company focused on developing improved, amorphous forms of TKIs, announces two poster presentations of data for XS004 in patients with chronic myeloid leukemia (CML) at the 64th annual American Society of Hematology (ASH) meeting December 10-13 in New Orleans, USA.
“As patients live longer with hematologic malignancies, there is a need to optimize treatments and improve patient experience over the long-term. Through our patented HyNap technology platform, Xspray develops improved amorphous oncology products with the potential to address real-world challenges that impact outcomes and quality of life. We are pleased to participate in ASH this year and present data that may be highly relevant for the CML community,” says Per Andersson, CEO of Xspray Pharma.
The US Food and Drug Administration (FDA) has granted XS004 orphan drug designation in the use of the treatment of chronic myeloid leukemia (CML). XS004 is currently under FDA review for market approval under the 505(b)(2) NDA regulatory pathway.
The following two abstracts will be presented:
Poster title: Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions
Poster number: 3013
First author: Gunnar Larfors, MD, PhD, Department of Medical Sciences, Unit of Hematology, Uppsala University, Sweden
Presentation date and location: Sunday, December 11, 6:00 PM – 8:00 PM, Ernest N. Morial Convention Center, Hall D
Poster title: XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use
Poster number: 4341
First author: Hans Lennernäs, Professor at Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Sweden
Presentation date and location: Monday, December 12, 6:00 PM – 8:00 PM, Ernest N. Morial Convention Center, Hall D